scholarly journals Essential amino acid supplementation in patients with severe COPD: a step towards home rehabilitation

2015 ◽  
Vol 77 (2) ◽  
Author(s):  
R.W. Dal Negro ◽  
A. Testa ◽  
R. Aquilani ◽  
S. Tognella ◽  
E. Pasini ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Placebo Group ◽  
Muscle Strength ◽  
Physical Performance ◽  
Daily Life ◽  
Cognitive Status ◽  
Fat Free Mass ◽  
Copd Patients ◽  
Severe Copd

Background. Pulmonary Rehabilitation (“Rehabilitation”) can improve both lung function and quality of life in patients suffering from chronic obstructive pulmonary disease (COPD) even if only a very small proportion of patients have access to Rehabilitation. Supplementation of Essential Amino Acids (EAAs) might allow COPD patients to achieve some typical Rehabilitation outcomes such as a better physical performance and an improved health status. Methods. 88 COPD out-patients (GOLD class 3-4) with a body mass index (BMI) <23 Kg/m2 were randomised to receive EAAs (n=44) or placebo (n=44) for twelve weeks. Primary outcome measures were changes in both physical activities in daily life (measured by Sense Wear Armband in terms of mean steps walked in one week) and in quality of life (measured by the St George’s Respiratory Questionnaire, SGRQ). Results. After 12 weeks, the physical performance was significantly increased vs baseline only in patients who received EAAs (1140.33 ± 524.69 and 638.68 ± 662.1 steps/day, respectively; p=0.02), being also the comparison vs the placebo group highly significant (p=0.003). Similarly, the SGRQ score improved significantly only in EAA patients (69.35 ± 9.51 vs baseline 72.04 ± 8.62; p<0.01), and changes were significantly different from those measured in the placebo group (p<0.001). Furthermore, when compared to those who received placebo, EAAs patients significantly increased their fat-free mass (p=0.04), muscle strength (p<0.01), saturation of oxygen (p=0.05), serum albumin (p<0.001), and also ameliorated their original cognitive dysfunction (p=0.02). Conclusions. Oral supplementation with EAAs contribute to improve the daily-life performance in domiciliary severe COPD patients who can not enter any Rehabilitation programme, together with their quality of life; nutritional and cognitive status, and muscle strength.

scholarly journals Clinical trial on the effects of oral magnesium supplementation in stable-phase COPD patients

2021 ◽  
Author(s):  
Bruno Micael Zanforlini ◽  
Chiara Ceolin ◽  
Caterina Trevisan ◽  
Agnese Alessi ◽  
Daniele Michele Seccia ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Placebo Group ◽  
Lung Function ◽  
Physical Performance ◽  
The Other ◽  
Stable Phase ◽  
Magnesium Supplementation ◽  
Copd Patients ◽  
Oral Magnesium

Abstract Background and aims COPD is a common chronic condition in older age that impacts on daily activities and quality of life. Previous studies suggest that magnesium deficit in COPD patients affects bronco-obstruction, inflammation, and physical performance. We investigated whether oral magnesium supplementation in stable-phase COPD patients improves lung function, physical performance, and quality of life. Methods We conducted a double-blind randomized-controlled clinical study with 49 participants divided into two groups: one given 300 mg/day of magnesium citrate (n = 25) and the other one sachet/day of a placebo (n = 24). The following parameters were assessed at baseline and after 3 and 6 months: lung function (spirometry), physical performance (handgrip strength, lower limb strength, six-minute walk test), inflammation (e.g., C-reactive protein, CRP), disease-related symptoms, and quality of life (St George’s Respiratory Questionnaire, EuroQoL-5D, the Modified British Medical Research Council Questionnaire). Results Linear mixed models revealed significantly lower CRP values in the intervention group than in the placebo group at the 6 month follow-up (β = − 3.2, 95% CI − 6.0, − 0.4, p = 0.03). Moreover, the maximum work for flexion tended to increase in both groups between the 3 and the 6 month assessments, especially in the placebo group. No significant differences within and between groups over the study period were observed for the other parameters tested. Conclusions Although the established minimum sample size was not reached, our results suggests that oral magnesium supplementation may have a potential anti-inflammatory role. On the other hand, it does not seem to substantially influence lung function, physical performance, and quality of life in COPD patients. Trial registration The study is registered in clinicaltrial.gov (Trial Registration: NCT02680769, 13 June 2016, retrospectively registered).

scholarly journals The Effect of Ophiocephalus Striatus Extract on suPAR, Neutrophil Levels and Lung Diffusion Capacity (DLCO) in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients with Muscle Wasting

2019 ◽  
Vol 39 (2) ◽  
pp. 79-87
Author(s):  
Sasongko Adhi Nugroho ◽  
Teguh Rahayu Sartono ◽  
Susanthy Djajalaksana ◽  
Harun Al Rasyid
Keyword(s):  
Quality Of Life ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Muscle Wasting ◽  
Fat Free Mass ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Diffusion Capacity ◽  
Copd Patients

Background: Muscle wasting is one of the extrapulmonary manifestation which influence quality of life in Chronic Obstructive Pulmonary Disease (COPD) patients. It caused by imbalance of protein metabolism in skeletal muscle. This study aimed to evaluate the effect of Ophiocephalus striatus extract on neutrophil count, soluble urokinase-type plasminogen activator (suPAR) level, diffusion capacity of lung for carbon monoxide (DLCO) and quality of life in stable COPD patients with muscle wasting. Methods: Clinical pre and post quasi experimental study was conducted to 32 stable muscle-wasted COPD patients from Pulmonary Outpatient Clinic Saiful Anwar Hospital Malang, determined by The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016, Bioelectrical impedance analysis (BIA) dengan fat-free mass (FFM)

scholarly journals Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitor—Induced Musculoskeletal Symptoms: A Pilot Randomized Clinical Study

2021 ◽  
Vol 11 (12) ◽  
pp. 1369
Author(s):  
Alessandro de Sire ◽  
Lorenzo Lippi ◽  
Antonio Ammendolia ◽  
Carlo Cisari ◽  
Konstantinos Venetis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Muscle Strength ◽  
Physical Exercise ◽  
Aromatase Inhibitor ◽  
Physical Performance ◽  
Whole Body Vibration ◽  
Musculoskeletal Symptoms ◽  
Whole Body

In this study, we aimed to assess the safety and efficacy of physical exercise, with or without whole-body vibration (WBV), in patients with aromatase inhibitor-induced musculoskeletal symptoms (AIMSS). Eligible patients were adults (≥18 years) with a history of breast cancer and current AIMSS. Enrolled patients (n = 22) were randomly assigned 1:1 to receive physical exercise combined with WBV or sham WBV for 4 weeks. The primary endpoint was pain intensity measured by numerical pain rating scale (NPRS). The secondary endpoints were muscle strength, physical function, physical performance, and quality of life. The WBV group (mean age: 51.73 ± 10.73 years; body mass index (BMI): 25.56 ± 5.17 kg/m2) showed a statistically significant pain reduction (NPRS: 6.82 ± 1.17 vs. 5.73 ± 1.01; p = 0.031), whereas patients in the sham WBV group (mean age: 58.55 ± 9.71 years; BMI: 27.31 ± 3.84 kg/m2), did not reach statistical significance (NPRS: 6.91 ± 2.02 vs. 5.91 ± 2.51; p = 0.07). Concurrently, muscle strength, physical performance, and quality of life significantly improved in both groups, without significant differences between groups. No dropouts and no side effects were recorded. Both patients and the physical therapist reported a high level of satisfaction with the intervention. Our findings suggest that physical exercise and WBV combination might be a safe therapeutic option for improving the rehabilitative management of patients with AIMSS.

A cross-sectional study in severe COPD patients in the Middle East and Africa (MEA): Symptoms variability and quality of life

2018 ◽  
Author(s):  
Nurdan Kokturk ◽  
Medhat Soliman ◽  
Amr Albanna ◽  
Richard Van Zyl Smit ◽  
Elmas Malvolti ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Middle East ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Copd Patients ◽  
Severe Copd

scholarly journals Physical Performance and Quality of Life in Older Adults: Is There Any Association between Them and Potential Drug Interactions in Polymedicated Octogenarians

2019 ◽  
Vol 16 (21) ◽  
pp. 4190 ◽  
Author(s):  
Verde ◽  
García de Diego ◽  
Chicharro ◽  
Bandrés ◽  
Velasco ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Older Adults ◽  
Drug Interactions ◽  
Physical Performance ◽  
Poor Quality ◽  
Potential Interaction ◽  
Cognitive Status ◽  
Community Dwelling ◽  
Increased Risk

Older adults are at increased risk of several cytochrome P450 (CYP) drug interactions that can result in drug toxicity, reduced pharmacological effect, and adverse drug reactions. This study aimed to assess the prevalence of potential CYP interactions referring to the most clinically relevant drugs and exploring the relationship between them and quality of life and physical performance in Spanish octogenarians. Institutionalized and community-dwelling octogenarians (n = 102) treated at three primary care centers, were recruited by a research nurse. Anthropometric measurements, chronic diseases, prescribed drugs, quality of life, physical performance, mobility skills, hand grip strength and cognitive status data were collected. Potential CYP drug-drug interactions (DDIs) were selected referring to the main CYP implicated in their metabolism. The 72.2% of recruited octogenarians presented potentially inappropriate CYP inhibitor-substrate or CYP inductor-substrate combinations. Analyzing the EuroQol Visual Analogue scale (EQ-VAS) results, patients with a potential CYP DDI perceived worse health status than patients without it (p = 0.004). In addition, patients with a potential CYP DDI presented worse exercise capacity, kinesthetic abilities, or mobility than those who didn’t present a potential interaction (p = 0.01, p = 0.047, and p = 0.02, respectively). To investigate and control factors associated with loss of muscle strength and poor quality of life, polypharmacy and DDIs could help institutions in the management of physical frailty.

scholarly journals Improvement of Physical Performance and Quality of Life After Rehabilitation Program for Total Knee Replacement in Geriatric Patient

2020 ◽  
Vol 8 (01) ◽  
pp. 26-34
Author(s):  
Andi Dala Intan ◽  
Juan Suseno
Keyword(s):  
Quality Of Life ◽  
Muscle Strength ◽  
Total Knee Replacement ◽  
Physical Performance ◽  
Knee Replacement ◽  
Geriatric Patient ◽  
Medical Rehabilitation ◽  
Pain Patient ◽  
Total Knee

Introduction: Early medical rehabilitation after Total Knee Replacement (TKR) was necessary to optimize healing process and reduce pain postoperative that can restrain patients’ activity.Case Presentation: A 66-years-old women had right TKR due to osteoarthritis genu dextra with chronic pain. Patient has muscle weakness on affected leg, and still not able to walk. Medical Rehabilitation(MR) program started one day after surgery for 4 weeks. After 4 weeks of MR program, patient had mild pain, and can walk for 100 m. Pain intensity by visual analogue scale (VAS) reduced from 7/10 to2/10, knee flexion increased from 70° to120°, right quadriceps muscle strength increased from 4 to 5 by manual muscle test (MMT), time to do physical performance by time up and go (TUG) was reduced from15 to 12.8 sc, activity daily living (ADL) by Barthel Index sco re increased from 4 to 8.Conclusion: Four weeks Rehabilitation Medicine program in geriatric patient with post Right TKR for 4 weeks, effective to improved muscle strength, balance, and ADL.Keywords: Medical rehabilitation, total knee replacement, geriatric, physical performance, quality of life

scholarly journals Almitrine bismesylate treatment in patient with chronic obstructive pulmonary disease and moderate chronic respiratory failure. Open prospective multicentre trial

2005 ◽  
pp. 92-100 ◽  
Author(s):  
A. G. Chuchalin ◽  
S. N. Avdeev ◽  
A. V. Bezlepko ◽  
V. A. Dobrich ◽  
V. A. Ignatiev ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multicentre Trial ◽  
Daily Life ◽  
Chronic Obstructive ◽  
Life Questionnaire ◽  
Obstructive Pulmonary Disease ◽  
Almitrine Bismesylate ◽  
Daily Life Activities ◽  
Copd Patients

The efficacy and safety of almitrine bismesylate treatment was assessed in COPD patients in 6 month open prospective multicentre trial. 77 COPD patients with moderate hypoxemia were included (males / females — 57 / 20, mean age 63.2 ± 9.7 years; mean FEV1 0.95 ± 0.38 L, mean PaO2 63.3 ± 5.4 mmHg, mean PaСO2 44.1 ± 7.3 mmHg). We used an intermittent regime of almitrine administration: 1 mg / kg / day, for 3 months, then a "window" of 1 month, and again active therapy for 2 months. Almitrine therapy resulted in improvement of РаО2: rise after 1 month to 71.5 ± 10.6 mmHg, after 3 month — to 70.3 ± 8.3 mmHg, and after 6 month — to 72.5 ± 14.2 mmHg (р < 0.001). There was a significant fall in dyspnea during daily life activities (MRC score): from 3.5 ± 0.9 to 3.0 ± 0.9 (1 month), 2.8 ± 0.9 (3 month), 2.6 ± 0.7 (6 month) (р < 0.001). The distance during 6 minute walk test (6 MWT) increased from 334 ± 108 m to 371 ± 101 m (1 month), 377 ± 88 m (3 month), 398 ± 104 m (6 month) (р < 0.001). The levels of desaturation and Borg dyspnea score during 6 MWT significantly decreased (both р < 0.001). During almitrine treatment an improvement in almost all domains of SF 36 quality of life questionnaire was noted. 58 COPD patients completed the study. The most common adverse effects were parasthesia (6.4 %) and worsening of dyspnea (5 %), pulmonary artery pressure did not change during study. Conclusions: almitrine treatment in COPD patients with moderate hypoxemia resulted in improvement of arterial oxygenation, reduction of dyspnea during daily life activities and exercise, increase of physical capacity and improvement of health related quality of life.

scholarly journals Effect of malnutrition and body composition on the quality of life of COPD patients

2021 ◽  
Author(s):  
M. Fekete ◽  
V. Fazekas-Pongor ◽  
P. Balazs ◽  
S. Tarantini ◽  
G. Szollosi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Function ◽  
Nutritional Status ◽  
Normal Weight ◽  
Fat Free Mass ◽  
Nutritional Risk ◽  
Walking Distance ◽  
Chronic Obstructive ◽  
Copd Patients

AbstractBackgroundPathological alterations in nutritional status may develop in Chronic Obstructive Pulmonary Disease (COPD) patients through production of inflammatory cytokines and inadequate diet.ObjectiveThe aim of our study was to determine the correlation between nutritional status and quality of life of COPD patients.MethodsWe evaluated the nutritional status of COPD patients of Hungarian National Koranyi Institute for Pulmonology using the Malnutrition Universal Screening Tool (MUST) and bioelectrical impedance analysis (BIA) between January 1 and June 1, 2019. Lung function, physical fitness, and respiratory muscle strength were included in the assessment.ResultsFifty patients (mean age was 66.3 ± 9.6 years) participated in our study. Mean body mass index (BMI) was 26.2 ± 6.1 kg/m2 and mean fat-free mass index (FFMI) was 16.8 ± 2.4 kg/m2. Overweight patients had better lung function values (FEV1ref%: 46.3 ± 15.2) than normal (FEV1ref%: 45.1 ± 20.9) and underweight patients (FEV1ref%: 43.8 ± 16.0). The Modified Medical Research Council Dyspnea Scale (mMRC) was significantly associated with various parameters; strongest correlation was found with FFMI (r = −0.537, P < 0.001), skeletal muscle mass index (SMMI) (r = −0.530, P < 0.001), and 6-minute walking distance (6MWD) (r = −0.481, P < 0.001).ConclusionsOur results indicate that malnourished COPD patients may have reduced lung function and lower quality of life compared to normal weight patients. Thus, our findings suggest that nutritional therapy be included in the treatment of COPD patients combined with nutritional risk screening and BIA during the follow-up.

Sign in / Sign up

Export Citation Format

Share Document